Investor presentation highlights rademikibart program
Connect Biopharma highlighted rademikibart, an anti-IL-4Rα antibody, as its lead program for eosinophilic-driven asthma, COPD.
Global Phase 2b asthma study showed rapid FEV1 gains within 24 hours; IV push dosing lifted FEV1 by over 100 mL within minutes.
Two Phase 2 trials in acute asthma, acute COPD exacerbations finished enrollment; topline data expected in Sep-2026.
FDA meeting targeted in 4Q2026 to align on Phase 3 for acute use; asthma likely prioritized if both acute studies read positive.
Presentation cited projected peak sales above $3 billion in asthma, above $2 billion in COPD; over 1,800 participants with no major drug-related safety issues.
CNTB•
